Global Binge Eating Disorder Market to Grow at a CAGR of 6.1% During the Period 2024-2032, Driven by Rising Awareness of the Condition

The global binge eating disorder market is expected to be driven by growing awareness of the condition and development of treatments for the disorder. The increasing number of doctors trained to treat the condition is also expected to contribute to market growth. North America, Europe and Asia are expected to be key markets.

Binge eating disorder may be seen in across all age groups, races, and income levels, however, it seems most prevalent among women. Among men, it is the most common eating disorder. Several companies are engaged in developing new treatments for the disorder. For example, in 2022, Tonix Pharmaceuticals Holding Corp. and Massachusetts General Hospital announced an agreement to assess TNX-1900 as a probable treatment for patients with binge eating disorder. The investigator-initiated phase 2 clinical trial, which was expected to launch in the second half of 2022, would be a randomized, double-blind, placebo-controlled study of 60 patients diagnosed with both binge eating disorder and obesity.

Vyvanse® (lisdexamfetamine dimesylate) is a central nervous system stimulant specified for the treatment of moderate to acute binge eating disorder and attention deficit hyperactivity disorder. Shire presented a supplemental new drug application for Vyvanse® for the treatment of moderate to severe binge eating disorder in adults to the FDA in July 2014. The drug received approval by the FDA for the indication in January 2015. Vyvanse® was also approved in Australia for both the conditions and in Canada, Europe, and Brazil for the treatment of ADHD. Vyvanse® is a key brand of Takeda under the neuroscience therapeutic area.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

In 2018, Chronos Therapeutics Ltd (Chronos) announced that the lead compound in its addiction programme, CT-010018 an orexin-1 antagonist, demonstrated positive pre-clinical proof of concept (POC) results in an in vivo model of binge eating disorder. Such developments are expected to boost the global binge eating disorder market. Orexin-1 antagonism was seen as an attractive target in binge eating disorder. Targeting this brain system had the promise to offer an effective treatment of binge eating disorder with no abuse liability, anhedonia, anorexia or somnolence.

In 2019, VIVUS announced the results of a clinical study (NCT02553824) demonstrating that patients with binge-eating disorder or bulimia nervosa receiving Qsymia (phentermine and topiramate extended-release (ER)) capsules CIV showed significant reduction in binge day frequency compared to placebo over four weeks.  Also, Qsymia was well tolerated in these patient populations.

Key Findings of the Study:

• The global binge eating disorder market is expected to be driven by rising people’s awareness of the disorder and increasing number of doctors trained to treat the condition.

• Developments in treatment systems are likely to boost market growth.

• North America, Europe and Asia are projected to be key markets.

Market Analysis by Treatment, Distribution Channel and Region:

• By treatment, the market is segmented into Medication (further broken down by type into Antidepressant, Anticonvulsant, Anti-obesity Medication, and Others), Services (further broken down by type into Inpatient and Outpatient).

• By distribution channel, the market is classified into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy.

• By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790